CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline

March 11, 2026 8:35 AM

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (the "Company"), a biotechnology company focused on building a pipeline of innovative therapies in high-value neurology and oncology markets, today announced that it has launched a new corporate growth strategy designed to build a high-value pipeline in neurology and oncology. The strategy is being led by the newly formed executive team with deep experience across neurology, oncology and rare disease drug...

Read more

Wellgistics Strengthens PharmacyChain(TM) with Insurance Eligibility & Benefits Verification Capabilities

March 11, 2026 8:30 AM

Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has secured contractual rights to preferred pricing for medical insurance eligibility and benefits verification (EBV) that enables PharmacyChain...

Read more

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

March 11, 2026 8:30 AM

NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, is pleased to announce that it will be presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, Florida.NanoViricides announces herewith that the manufacture of the drug product for this clinical trial, "NV-387 Oral Gummies" is now complete, in anticipation of starting dosing...

Read more

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

March 11, 2026 7:30 AM

Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, is pleased to announce two important intellectual property milestones for bucillamine: (i) the filing of the U.S. and Canadian national phase patent applications under PCT/CA2024/000008 for "Compositions, Methods and Uses of Bucillamine in the Treatment of a Victim Exposed...

Read more

NAD+ Umbrella Labs Expands Research Use Only Access To Two Standardized Formats For High Rigor Redox, Metabolic Flux, And Mitochondrial Bench Science

March 11, 2026 5:45 AM

Umbrella Labs is providing NAD+ as a laboratory developmental research use only reference material intended for controlled experimental systems that interrogate redox balance, energy metabolism, and NAD+-dependent enzyme activity. This press release describes research considerations for NAD+ workflows where reproducibility depends on consistent identity fields, consistent storage assumptions, and consistent handling practices across repeated...

Read more

CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth

March 10, 2026 5:00 PM

CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in proven, science-backed natural ingredients and products, today announced that it has modified its existing outstanding notes to include a conversion feature pursuant to which the outstanding balance of the notes may be converted into common shares of the Company at a fixed conversion price of $0.06 per...

Read more

The $30 Billion CBD Question: Should Medicare Reimburse Cannabis Products Without FDA Approval?

March 10, 2026 4:00 PM

Why All CBD Is Not the Same - And Why FDA Standards MatterAs federal policymakers debate the proposed Medicare CBD pilot program, a critical scientific reality is often overlooked: not all CBD products are the same.While cannabidiol (CBD) is a single chemical compound, the products sold across the consumer marketplace vary dramatically in purity, formulation, manufacturing quality, and safety. These differences are precisely why the United...

Read more

MediQuant Expands Enterprise Archiving Platform to Help Health Systems Optimize Applications and Activate Legacy Clinical Data

March 10, 2026 10:05 AM

MediQuant, a leading healthcare application lifecycle and data management solutions provider and creators of DataArk, today announced expanded capabilities across its enterprise archiving platform designed to help healthcare organizations reduce application sprawl and make archived clinical data more accessible and actionable.Healthcare CIOs are under pressure to do more with existing systems as budgets tighten and operational risk increases. At...

Read more

Path Fertility Releases its Company Facts Sheet

March 10, 2026 10:05 AM

Path FertilityTM, an epigenetics-driven fertility technology company, today unveiled the Path Fertility Facts Sheet, a copy of which is embedded below within this news release.BEGINNING OF THE Path FertilityTM Facts SheetOverviewPath FertilityTM helps clinicians and patients uncover male-factor insights that can be missed by "Standard-of-Care" Semen Analysis testing alone, so couples can make more informed fertility treatment decisions...

Read more

VSee Unveils World's First Autonomous Telehealth AI Robot at HIMSS 2026

March 10, 2026 9:56 AM

VSee (NASDAQ:VSEE), the leader in telehealth platform innovation, today announced the launch of the VSee AI Robot at HIMSS 2026 - the world's first fully autonomous telehealth AI robot purpose-built for hospital and health system deployment. The VSee AI Robot enables remote clinicians to navigate directly to a patient's bedside without requiring onsite staff assistance, delivering true virtual rounding, rapid telestroke response, and specialist...

Read more

For Couples in "Fertility Limbo," a Real-World Study Published by JARG Finds "Normal" Semen Analysis May Not Tell the Whole Story

March 10, 2026 9:55 AM

A newly published, peer-reviewed study adds real-world evidence that some couples are stuck in "fertility limbo" even after a Semen Analysis comes back "normal."Recently published in the Journal of Assisted Reproduction and Genetics (JARG), the multi-clinic report found that while traditional Semen Analysis tests measure sperm count, movement, and shape, they do not directly measure whether sperm function well enough for certain fertility...

Read more

JinIX Foundation Marks a New Chapter with a Partner Event at Its Retreat Center

March 10, 2026 9:15 AM

JinIX Foundation welcomed a group of close partners to its private retreat center for a meaningful gathering held Feb. 20-Feb. 22. The weekend marked an important milestone for the Foundation. JinIX Foundation now has a dedicated physical home base where partners can gather with intention, build trust over time, and explore what long-term community work can look like in practice. JinIX Foundation is a nonprofit dedicated to supporting patients...

Read more

Kantesti Reports International Adoption of AI Enabled Laboratory Data Interpretation Platform

March 10, 2026 9:10 AM

Kantesti, a Germany based digital health software developer, announced continued international adoption of its artificial intelligence enabled platform designed to organize and interpret routine laboratory test results for individuals, healthcare providers, and enterprise clients. The company stated that users from more than 190 countries have accessed its AI blood test analyzer tools, which are intended to present biomarker values in a...

Read more

CVS Health Boosts CVS Pharmacy Customer Generosity To Address Food Insecurity

March 10, 2026 9:00 AM

CVS Pharmacy® customers donated more than $3 million last year to support local food banks across the country, and CVS Health® (NYSE:CVS) is boosting the overall contribution to support Feeding America. The in-store campaign, hosted at CVS Pharmacy locations nationwide, gave customers a simple and impactful way to contribute to the movement to end hunger in their own communities. CVS Health and its Foundation has also committed over $2 million...

Read more

AGAPE ATP Corporation Forges Strategic Collaboration with UAE-Based Citadel Investment

March 10, 2026 9:00 AM

NASDAQ-listed AGAPE ATP Corporation ("ATPC") through its subsidiary ATPC Green Energy Sdn. Bhd., has entered into a Collaboration Agreement with Citadel Investment LLC, a Dubai-based investment and global commodities trading firm, to jointly explore opportunities in oil, gas, petroleum products and petrochemical trading across international markets.Under the agreement, ATPC Green Energy and Citadel Investment will cooperate to identify,...

Read more

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

March 10, 2026 8:30 AM

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), today announced that its subsidiary, Buzz Bomb Caffeine Company, is expanding its retail footprint with the launch of the BUZZ BOMB™ Convenience Store Pack.Convenience stores are where many of today's quick decisions happen, and the checkout counter plays a big role in those moments. By introducing BUZZ BOMB™ into that space, we are giving the consumer greater choice and making BUZZ BOMB™...

Read more

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

March 10, 2026 8:30 AM

Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA)(Nasdaq:DRMAW), a science-driven leader in dermatologic solutions, today announced the appointment of Kyra Peckaitis as Vice President, Marketing. Ms. Peckaitis is a multi-disciplinary brand marketer and will lead Dermata's new brand launch, Tome Skincare. Ms. Peckaitis will oversee the marketing strategy, brand development, and consumer engagement initiatives as Tome gets...

Read more

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

March 10, 2026 8:05 AM

Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced new interim data for mipletamig in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) patients who are either elderly or unfit for intensive chemotherapy. In data from two trials, the...

Read more

Arthritis Foundation Announces 2026 Cycling Experiences With Three Ways to Ride and Support the Arthritis Community

March 10, 2026 8:00 AM

The Arthritis Foundation is preparing for its 2026 Cycling Experiences, featuring the Carolina Hills Classic Bike Tour, May 14-17, the California Coast Classic Bike Tour, Sept. 26-Oct. 3, and an expanded "Ride Your Way" option. Together, these three ways to participate give cyclists and supporters nationwide the opportunity to challenge themselves, build community and raise critical funds for the nearly 60 million adults and children in the U.S....

Read more

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

March 10, 2026 8:00 AM

Protagenic Therapeutics, Inc. (OTCQB:PTIX) ("Protagenic" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related disorders, including treatment-resistant depression and anxiety, today announced that its common stock has been upgraded from OTC Pink to the OTCQB® and has commenced trading on OTCQB under the symbol "PTIX."The OTCQB is a recognized public market for developing companies...

Read more